This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Is Second-Generation Antipsychotic-Induced Hyperprolactinemia Due to Biologically Active Prolactin or to Biologically Inactive Macroprolactin? Results From a Prospective Study

Alexander Tschoner, Julia Engl, Maria A. Rettenbacher, Susanne Kaser, Helmut W. Ott, W. Wolfgang Fleischhacker, Josef R. Patsch, and Christoph F. Ebenbichler

Published: February 16, 2009

Article Abstract

Letter to the Editor

Sir: Hyperprolactinemia is of particular concern with antipsychoticmedication, as symptoms associated with high prolactinlevels, e.g., sexual dysfunction, can have a negativeimpact on the patient’s adherence to treatment, and has significantimplications for the short-term and long-term health ofpatients. In general, second-generation antipsychotics (SGAs)produce lower increases in prolactin levels than first-generationantipsychotics due to the differences in these drugs’ binding affinityfor the dopamine D2 receptor. Particularly, olanzapine,quetiapine, and clozapine have been shown to produce no significantor sustained increase in prolactin. Conversely, SGAsthat have been associated with increases in prolactin levels areamisulpride, zotepine, and risperidone.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 70

Quick Links: